Cargando…

Costimulation of γδTCR and TLR7/8 promotes Vδ2 T-cell antitumor activity by modulating mTOR pathway and APC function

BACKGROUND: Gamma delta (γδ) T cells are attractive effector cells for cancer immunotherapy. Vδ2 T cells expanded by zoledronic acid (ZOL) are the most commonly used γδ T cells for adoptive cell therapy. However, adoptive transfer of the expanded Vδ2 T cells has limited clinical efficacy. METHODS: W...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Huaishan, Chen, Hui, Liu, Shujing, Zhang, Jie, Lu, Hezhe, Somasundaram, Rajasekharan, Choi, Robin, Zhang, Gao, Ou, Lingling, Scholler, John, Tian, Shifu, Dong, Liyun, Yeye, Guo, Huang, Lili, Connelly, Thomas, Li, Ling, Huang, Alexander, Mitchell, Tara C, Fan, Yi, June, Carl H, Mills, Gordon B, Guo, Wei, Herlyn, Meenhard, Xu, Xiaowei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8705233/ https://www.ncbi.nlm.nih.gov/pubmed/34937742 http://dx.doi.org/10.1136/jitc-2021-003339

Ejemplares similares

Transgenic CD8αβ co-receptor rescues endogenous TCR function in TCR-transgenic virus-specific T cells
por: Bajwa, Gagan, et al.
Publicado: (2020)

TCR-engineered adoptive cell therapy effectively treats intracranial murine glioblastoma
por: Schaettler, Maximilian O, et al.
Publicado: (2023)

In vivo therapeutic effects of affinity-improved-TCR engineered T-cells on HBV-related hepatocellular carcinoma
por: Liu, Qi, et al.
Publicado: (2020)

Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy
por: Liu, Xin, et al.
Publicado: (2022)

Cell-based artificial APC resistant to lentiviral transduction for efficient generation of CAR-T cells from various cell sources
por: Schmidts, Andrea, et al.
Publicado: (2020)

Engineering second-generation TCR-T cells by site-specific integration of TRAF-binding motifs into the CD247 locus
por: Lah, Sangjoon, et al.
Publicado: (2023)

TCR-engaging scaffolds selectively expand antigen-specific T-cells with a favorable phenotype for adoptive cell therapy
por: Tvingsholm, Siri Amanda, et al.
Publicado: (2023)

Treating solid tumors with TCR-based chimeric antigen receptor targeting extra domain B-containing fibronectin
por: Zhang, Zhijie, et al.
Publicado: (2023)

NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome
por: Ishihara, Mikiya, et al.
Publicado: (2022)

Δ133p53α enhances metabolic and cellular fitness of TCR-engineered T cells and promotes superior antitumor immunity
por: Legscha, Kevin Jan, et al.
Publicado: (2021)

Induction of EBV latent membrane protein-2A (LMP2A)-specific T cells and construction of individualized TCR-engineered T cells for EBV-associated malignancies
por: Zhang, Chaoting, et al.
Publicado: (2021)

Generation and characterization of HLA-A2 transgenic mice expressing the human TCR 1G4 specific for the HLA-A2 restricted NY-ESO-1(157-165) tumor-specific peptide
por: Shenderov, Eugene, et al.
Publicado: (2021)

TIPE2 deletion improves the therapeutic potential of adoptively transferred NK cells
por: Bi, Jiacheng, et al.
Publicado: (2023)

Novel potent anti-STEAP1 bispecific antibody to redirect T cells for cancer immunotherapy
por: Lin, Tsung-Yi, et al.
Publicado: (2021)

Generalizable design parameters for soluble T cell receptor-based T cell engagers
por: Froning, Karen J, et al.
Publicado: (2022)

4‐1BB costimulation promotes bystander activation of human CD8 T cells
por: Reithofer, Manuel, et al.
Publicado: (2020)

CBLB ablation with CRISPR/Cas9 enhances cytotoxicity of human placental stem cell-derived NK cells for cancer immunotherapy
por: Guo, Xuan, et al.
Publicado: (2021)

Delivery of CD47 blocker SIRPα-Fc by CAR-T cells enhances antitumor efficacy
por: Chen, Huanpeng, et al.
Publicado: (2022)

All-trans retinoic acid improves NSD2-mediated RARα phase separation and efficacy of anti-CD38 CAR T-cell therapy in multiple myeloma
por: Peng, Ziyi, et al.
Publicado: (2023)

Bufalin stimulates antitumor immune response by driving tumor-infiltrating macrophage toward M1 phenotype in hepatocellular carcinoma
por: Yu, Zhuo, et al.
Publicado: (2022)

Identification of novel HLA-A*11:01-restricted HPV16 E6/E7 epitopes and T-cell receptors for HPV-related cancer immunotherapy
por: Xiong, Chengjie, et al.
Publicado: (2022)

Targeting human leukocyte antigen G with chimeric antigen receptors of natural killer cells convert immunosuppression to ablate solid tumors
por: Jan, Chia-Ing, et al.
Publicado: (2021)

Immunosuppressant indulges EBV reactivation and related lymphoproliferative disease by inhibiting Vδ2(+) T cells activities after hematopoietic transplantation for blood malignancies
por: Liu, Jiangying, et al.
Publicado: (2020)

Framework humanization optimizes potency of anti-CD72 nanobody CAR-T cells for B-cell malignancies
por: Temple, William C, et al.
Publicado: (2023)

Intrinsic suppression of type I interferon production underlies the therapeutic efficacy of IL-15-producing natural killer cells in B-cell acute lymphoblastic leukemia
por: Kumar, Anil, et al.
Publicado: (2023)

Bone marrow MSC from pediatric patients with B-ALL highly immunosuppress T-cell responses but do not compromise CD19-CAR T-cell activity
por: Zanetti, Samanta Romina, et al.
Publicado: (2020)

Point mutation in CD19 facilitates immune escape of B cell lymphoma from CAR-T cell therapy
por: Zhang, Zhen, et al.
Publicado: (2020)

Adherent cell depletion promotes the expansion of renal cell carcinoma infiltrating T cells with optimal characteristics for adoptive transfer
por: Braun, Mitchell W, et al.
Publicado: (2020)

Nanopore sequencing as a scalable, cost-effective platform for analyzing polyclonal vector integration sites following clinical T cell therapy
por: Zhang, Ping, et al.
Publicado: (2020)

41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo
por: Baroni, Matteo Libero, et al.
Publicado: (2020)

Sensitive manipulation of CAR T cell activity using a chimeric endocytosing receptor
por: Zhang, Boning, et al.
Publicado: (2020)

CAR-T cells and TRUCKs that recognize an EBNA-3C-derived epitope presented on HLA-B*35 control Epstein-Barr virus-associated lymphoproliferation
por: Dragon, Anna Christina, et al.
Publicado: (2020)

PD-1 inhibitor inducing exosomal miR-34a-5p expression mediates the cross talk between cardiomyocyte and macrophage in immune checkpoint inhibitor–related cardiac dysfunction
por: Xia, Wenzheng, et al.
Publicado: (2020)

Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses
por: Brempelis, Katherine J, et al.
Publicado: (2020)

Human macrophages engineered to secrete a bispecific T cell engager support antigen-dependent T cell responses to glioblastoma
por: Gardell, Jennifer L, et al.
Publicado: (2020)

Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma
por: Borch, Troels Holz, et al.
Publicado: (2020)

Safety and efficacy of CAR-T cell targeting BCMA in patients with multiple myeloma coinfected with chronic hepatitis B virus
por: Han, Lu, et al.
Publicado: (2020)

Rapid tumor vaccine using Toll-like receptor-activated ovarian cancer ascites monocytes
por: Adams, Sarah F, et al.
Publicado: (2020)

Efficient elimination of primary B-ALL cells in vitro and in vivo using a novel 4-1BB-based CAR targeting a membrane-distal CD22 epitope
por: Velasco-Hernandez, Talia, et al.
Publicado: (2020)

Local injection of CCL19-expressing mesenchymal stem cells augments the therapeutic efficacy of anti-PD-L1 antibody by promoting infiltration of immune cells
por: Iida, Yuichi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ogm1fmhvaunvbgi7r2smoaijcj